Abstract
BACKGROUND Several diagnostic and prognostic biomarkers are being explored in heart failure. GDF-15 belongs to the transforming growth factor β (TGF-β) cytokine family that is highly up regulated in inflammatory conditions. We undertook this systematic review to summarize the current evidence on the utility of GDF-15 as a biomarker in heart failure. DESIGN AND METHODS Multiple electronic databases for studies that reported the association between GDF- 15 and heart failure were searched using different electronic databases such as MEDLINE, Science Direct, Springer Link, Scopus, Cochrane Reviews, and Google Scholar using pre-defined inclusion- exclusion criteria. RESULTS Twenty one original studies were identified that included data from 20,920 study participants. GDF 15 was found to be a strong prognosticator of all-cause mortality in heart failure patients. Several studies found the benefit of using GDF-15 as a component of a multi-biomarker strategy in prognosticating patients with heart failure. CONCLUSION More studies are warranted to elucidate the molecular pathways involving GDF-15 and to see how knowledge about GDF-15 can be used to make therapeutic decisions in the clinic.
Cite
CITATION STYLE
George, M., Jena, A., Srivatsan, V., Muthukumar, R., & Dhandapani, V. (2016). GDF 15 - A Novel Biomarker in the Offing for Heart Failure. Current Cardiology Reviews, 12(1), 37–46. https://doi.org/10.2174/1573403x12666160111125304
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.